New Alzheimer’s drug rejected from PBS
Update: 2025-08-29
Description
An application to include a drug to treat the early symptoms of Alzheimer's disease on the Pharmaceutical Benefits Scheme (PBS) has been rejected.
The committee in charge of making the decision has ruled the potential benefits of the drug donanemab are too small, and the burden for both patients and the health system too large.
In other news, a new study has highlighted the benefits of lifestyle interventions in staving off cognitive decline in people at high risk.
References
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
